Drugs / KK8398
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06926491 | Dec 2024 → May 2029 expected | achondroplasia | Kyowa Kirin, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | Kyowa Kirin, Inc. | Results Kyowa Kirin Highlights Publication in the New England Journal of Medicine of BridgeBio’s Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia kyowakirin.com ↗
BridgeBio reported that positive results from PROPEL 3, a global pivotal Phase 3 study evaluating oral infigratinib, were published as an original research article in NEJM and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026. |
| 2026-02-16 | Kyowa Kirin, Inc. | Results Kyowa Kirin Highlights Positive Phase 3 Topline Data from BridgeBio’s Global PROPEL 3 Study of Infigratinib in Achondroplasia kyowakirin.com ↗
The topline data demonstrated that the primary endpoint was achieved, revealing high efficacy and favorable tolerability. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK8398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06926491 ↗ |
| Known as | Infigratinib | “A Multicenter, Open-label, Single-arm, Phase 3 Study of KK8398 (Infigratinib) in Patients With Achondroplasia (AOBA Study)” NCT06926491 ↗ |